Getting in the MOUD: Medications for Opioid Use Disorder

- Presenters: Diep Ngo, PharmD and Alexi Duenas, PharmD
- Kelley-Ross Pharmacy Group
- August 11, 2022
- WA Poison Control Overdose Awareness Series





Agenda

Background

Medications

Access

Mythbusting

Summary

Q & A



POLL QUESTION 1:

- Who is in our audience today?
 - –Prescriber
 - -Behavioral Health Care Provider
 - –Public Member
 - Other healthcare professional




BACKGROUND



Laying the groundwork: What drugs are opioids?

- Synthetic: methadone, tramadol, fentanyl
- Semi-synthetic: oxycodone, hydrocodone, oxymorphone
- Natural: morphine, codeine

Don't forget: combination products!



Building our foundation: How and where do opioids work in the body?

- **HOW:** Attachment to endogenous opioid receptors in the body.
- •WHERE: Receptors everywhere! Notably in the brain, brain stem, spinal cord, and intestines. Opioid receptors are known as κ , Δ and μ .
- WHY? Fun fact: our body produces its own opioids, called enkephalins and endorphins.



Important distinction:


- Tolerance: when a person using opioids experiences a reduced response to treatment and will require more medication to get the same effect
- Dependence: when the body adjusts its functioning around opioid use and unpleasant physical symptoms occur if the drug is stopped
- Addiction (what we will call opioid use disorder): when attempts to decrease opioid intake are unsuccessful, resulting in a lack of fulfillment of obligations professionally and personally





Structural changes: How do people become addicted to opioids?

The bulk of executive



Opioids suppress release of norepinephrine here.

Structural changes: How do people become addicted to opioids?

Theory 1: Changed Set Point (VTA)

- Without OUD: neurons release fixed amount of dopamine
- With OUD: opioids change the "set point" so more dopamine is required for pleasure

Theory 2: Cognitive Deficits (PFC)

- Without OUD: dopamine signaling inhibited, helping us overcome impulsivity
- With OUD: dopamine signaling impaired, ability to control impulses damaged



Who is at risk for OUD?

EVERYONE!

Especially those with:


- Externalizing traits
- Family, peer, and social/environmental factors:
 - Other substance
 use disorder, anti social behavior, and
 disinhibitory
 personality traits
- Genetic markers...





Hot off the press!

Deak et al., 2022







MEDICATIONS




POLL QUESTION 2:

- What medication for OUD would you like to learn the most about today?
 - -Methadone
 - -Naltrexone
 - —Buprenorphine
 - -Buprenorphine/Naloxone



How medications for OUD work in the brain





Safe in pregnancy!

Methadone

Mechanism

 \bullet Long-acting agonist at $\mu\text{-opioid}$ receptors that decreases craving and withdrawal and blocks the effects of opioids



Dose

• Formulations: liquid, tablet

Side Effects

- Common: restlessness, N/V, slower breathing, constipation
- Severe: Difficulty or shallow breathing, chest pain, hallucinations

- Other indications: methadone for pain vs. methadone for OUD
- Restrictions: Initially under directly observed therapy (DOT), then can be taken on own after a period of stability. May only be prescribed for OUD within a SAMHSA-certified Opioid Treatment Program.
- Duration of therapy: varies, but minimum of 12 months
- Non-linear kinetics and drug-drug interactions!



LIMITED DATA in pregnancy!

Naltrexone



Mechanism

• Opioid antagonist- binds and blocks opioid receptors and reduces cravings. It is not an opioid and it is not an addictive substance.

Dose

• Formulations: injection (Vivitrol) administered every 4 weeks.

Side Effects

- Common: injection site reactions, decreased appetite, muscle aches
- Severe: liver damage, depressed mood, pneumonia

- Other indications: tablet and injection indicated for alcohol use disorder
- To reduce the risk of withdrawal, patients need to wait 7-14 days before starting. Needs to be administered by clinician.
- May not be the best choice for HIV positive patients.





Buprenorphine



Mechanism

ullet Partial agonist at μ -opioid receptors that decreases craving and withdrawal

Dose

• Formulations: sublingual tablet daily, injection monthly, implant

Side Effects

- Common: headache, nausea, vomiting, constipation, sweating, dry mouth, dental problems (including tooth decay)
- Severe: difficulty breathing, low blood pressure, overdose, prolonged QTc

- Other indications: pain
- Restrictions: prescribers require an XDEA (waiver certification or if exempted, limited to 30 patients at any one time)
- Achieve stable dose within days
- Lower risk of misuse, but it can still occur



Safe in pregnancy!

Buprenorphine/Naloxone (Suboxone)



Mechanism

- ullet B: Partial agonist at μ -opioid receptors that decreases craving and withdrawal
- N: opioid antagonist, added to decrease potential for misuse

Dose

Formulations: sublingual film daily, sublingual tablet daily

Side Effects


- Common: headache, nausea, vomiting, constipation, sweating, dry mouth, dental problems (including tooth decay)
- Severe: difficulty or shallow breathing, low blood pressure, overdose

- Restrictions: prescribers require an XDEA (waiver certification or if exempted, limited to 30 patients at any one time)
- Achieve stable dose within days



Do these treatments work?

 Wakeman et al. 2020: Buprenorphine or methadone treatment for OUD was associated with reductions in overdose and serious opioid-related acute care.



POLL QUESTION 3:

Despite the many effective treatments available, only 11.2% of people with OUD were treated for it in 2020.

- 33.5%
- 11.2%
- 60.4%
- 5.5%



ACCESS



Considerations for Choosing

		Methadone	Naltrexone	Buprenorphine	Buprenorphine /Naloxone		
	Setting	SAMHSA-certified Opioid Treatment Programs (OTP) dispense for daily administration in clinic or at home (stable patients)	Clinic-based for monthly administration	SL: Outpatient (often induction) Injection/Implant: Clinic-based for administration or insertion/removal	Outpatient (often maintenance)		
				pharmacy, but bupr	be filled & dispensed from a cy, but buprenorphine/naloxone is more expensive		
	Prescribers	Providers with DEA at an OTP	Anyone that can prescribe	 Providers (physician, NP, PA, CNSs, CRNAs, CNMs) with an XDEA either by waiver certification or exemption Certification in REMS programs for Sublocade and Probuphine 			
	Patient	 Lives in proximity and has availability to attend daily Needs structure History of noncompliance Safe in pregnancy 	 Does not want agonist therapy High motivation for abstinence Short or less severe OUD history Has been detoxed from opioids 	 Not tolerating wi Cannot go to dail Safe in pregnance 	ly clinic		





COVID-19 Response

- Telemedicine & Telephone
 - Allows practitioners to prescribe buprenorphine to new and existing patients with OUD via telemedicine or telephone without first conducting an exam in-person
 - OTP may dispense up to 14 doses of MAT for clinically less stable patients and 28 doses for clinically stable patients
- Off-site delivery
 - Allows OTPs to deliver methadone or buprenorphine to their patients repeatedly from an off-site location without separately registering with the DEA

Finding Treatment



Opioid Treatment Program Directory

Select to view the opioid treatment programs in a State




Buprenorphine Practitioner Locator

Find practitioners authorized to treat opioid dependency with buprenorphine by state.

Select a state from the map or use the drop down lists to view all of the practitioners waived to provide buprenorphine for the treatment of OUD in a city, state or zip code.

Please note that this list only contains the contact information from practitioners who consent to release their practice information. Therefore, this list is not inclusive of all waivered practitioners.

Practitioners are responsible for updating their contact information. To update practice information, complete the <u>Update Practitioner Profile form</u>.



ZIP Code	Distance from ZIP			
	25 Miles	~		

Opioid treatment programs in Washington: 35											
1 <u>2</u>											
Program Name	Street	<u>City</u>	State	Zip Code	Phone	Certification	First Full Certification Date/CMS Use	Мар			
BAART Behavioral Health Services, Inc.	1520 NE Riddell Road, Suite 110	Bremerton	WA	98310	(360) 228-7246	Certified	03/23/2021	<u>Map</u>			






 Substance Use Mental Health

Google

 Health Care Centers Buprenorphine Practitioners

Vigor



locator/

T-Mobile Pa

Krispy Kreme

Keyboard shortcuts

Find Facility


☐ State

https://www.warecoveryhelpline.org/moud-

Seattle, WA, USA

☐ County

☐ Distance 5 ∨ miles




Psychosocial Support

Includes assessment of psychosocial need, counseling, connections to family support, referrals to community services



Benefits: increase engagement, change attitudes and behaviors, address co-occuring mental disorders



Additional Resources

- Narcotics Anonymous is a program that uses a 12-step model for those with OUD
 - https://www.na.org/ Find local or virtual meetings and information
 - https://nachatroom.org/ 24/7 online chatroom
- Smart Recovery is a support group focused on self-empowerment
 - <u>https://www.smartrecovery.org/</u> Find toolbox, forums, and specialized support groups
- Women For Sobriety is specifically tailored to help women in recovery address unique their unique needs and challenges
 - https://womenforsobriety.org/ Find meetings, online forum, and more about the WFS Annual Weekend Conference
- SAMHSA
 - https://store.samhsa.gov/ Find tip sheets, fact sheets, information guides



Family and Friends

- Nar-Anon Family Groups provides group meetings for family and friends of those with OUD. Narateen is designed for teen members.
 - www.nar-anon.org
- Parents of Addicted Loved Ones
 (PAL) provides resources and group meetings for parents of adult children with substance use disorder
 - https://palgroup.org/
- Learn to Cope provides resources, group meetings, and a forum for family members and friends of those with substance use disorder
 - https://learn2cope.org/





Expanding Access

- Mobile Narcotic Treatment Programs (NTP)
 - Add mobile component to existing registration for an NTP rather than requiring a separate registration
- 3-Day supply
 - Practitioners in hospitals, clinics, and emergency rooms can request exception that allows dispensing of 3-day supply of MAT to treat acute opioid withdrawal symptoms
- Buprenorphine Exemption → MAT ACT




MYTHBUSTING



1) If someone close to me was addicted to opioids, I would be able to tell.

Figure 18. Source Where Pain Relievers Were Obtained for Most Recent Misuse: Among People Aged 12 or Older Who Misused Pain Relievers in the Past Year; 2020



9.3 Million People Aged 12 or Older Who Misused Pain Relievers in the Past Year

FALSE!



1) If someone close to me was addicted to opioids, I would be able to tell.


According to the DSM-5:

A problematic pattern of opioid use leading to clinically significant impairment or distress, as manifested by at least two of the following, occurring within a **12-month period**:

- Opioids are often taken in larger amounts or over a longer period than was intended.
- A great deal of time is spent in activities necessary to obtain the opioid, use the opioid, or recover from its effects.
- Craving, or a strong desire or urge to use opioids.
- Important social, occupational, or recreational activities are given up or reduced because of opioid use.
- Tolerance, as defined by either of the following:
 - A need for markedly increased amounts of opioids to achieve intoxication or desired effect.
 - •Note: This criterion is not considered to be met for those taking opioids solely under appropriate medical supervision.



2) People with OUD can stop taking their medication at any time but choose not to stop.



It's a GREY matter.



3) The medications used for treating OUD are replacing one addiction for another

Theory 1: Changed Set Point (VTA)

Theory 2: Cognitive Deficits (PFC) MAT blocks the euphoric effects of opioids and relieve physiological cravings while minimizing withdrawal symptoms.

Essentially, it normalizes body function without the negative and euphoric effects of the substance used

FALSE!



4) You should have naloxone (Narcan) on hand even if you are taking a medication for OUD.



TRUE!



5) Taking opioid pain medications always leads to addiction. You should avoid using it altogether!

Taking opioids does not always lead to addiction. Per the CDC, "as many as one in four patients receiving long-term opioid therapy in a primary care setting struggles with opioid addiction."

- We <u>DO NOT</u> want to deny people adequate pain management. There are times when opioids are appropriate treatment options.
- Potential benefits of prescribing an opioid pain medication must <u>always be weighed</u> against potential risks of using the medication (including dependence and addiction)
- Rules and prescribing limits in place to try to <u>limit duration of</u>
 <u>use</u> to reduce risk of dependence

FALSE!



Summary

Opioid use disorder is a medical condition that causes neurobiological changes in the brain that impair decision making and change reward pathways.

Choice in medication should be
 individualized to both patient's physical health and psychosocial factors.

There are many resources available to both individuals, family, friends, and providers for seeking treatment and support.

Addressing misconceptions about opioid use disorder to reduce stigma is an important avenue to increase access.



Q & A

For any additional questions, please reach out

- Alexi Duenas: <u>aduenas@kelley-ross.com</u>
- Diep Ngo: dngo@kelley-ross.com



